Supporters can expect Muscular Dystrophy UK to deliver on our three-part promise to you:
Funds are guaranteed to be restricted for this purpose in line with donor wishes.
Muscular Dystrophy UK employs a stringent selection process for the grants it funds. The peer review process is rigorous and uses independent experts. The grants are also evaluated by our well-established and respected Medical Research Committee which comprises renowned scientists and clinicians.
This is complemented by input from our Lay Research panel, consisting of individuals directly or indirectly affected by a neuromuscular condition to ensure that the opinions of our supporters are taken into account in the award making process.
We fund only good quality science, ensuring no duplication of funding; discipline in monitoring and reporting; excellent interpretation/communication of results to those affected by Duchenne muscular dystrophy.
Partners and major individual donors who wish to have a decision-making role can join our ‘Duchenne Network’ – with involvement in the allocation of funds to key approved projects.
Through the Network Muscular Dystrophy UK brings families together with the leading scientists to hear the latest progress in the fight against Duchenne muscular dystrophy. The network currently meets twice per year and is open for anyone to attend.
We will work effectively with partners. In 2013, Muscular Dystrophy UK brought together UK charities with an interest in accelerating progress in the search for an effective treatment and ultimately a cure for Duchenne muscular dystrophy. This funding partnership, known as the Duchenne Forum, has allowed additional research to be funded. It has supported seven pioneering Duchenne research projects in 2013 and a further three research projects in 2014. Last year, Muscular Dystrophy UK was delighted to be a partner of the Newcastle plan and to make a major contribution towards boosting clinical trials capacity in the UK.
We are committed to ensuring effective communications with key influencers – regulatory bodies, parliaments, the worldwide scientific community, the biopharma industry and the media.
Working together, we can ensure that consistent and powerful messages are heard, action is taken and all those empowered to deliver for people with Duchenne muscular dystrophy are held to account.
Support the Duchenne Research Breakthrough Fund now.